ACR 5.45% 5.8¢ acrux limited

Bio stocks on road to recoveryJustin Bailey6 October...

  1. 366 Posts.
    Bio stocks on road to recovery
    Justin Bailey
    6 October 2010
    Australian Financial Review

    According to Sebastian Evans, fund manager at Naos Asset Management, four of five biotechnology stocks could end up turning into billion-dollar companies. Eli Lilly, Roche and Pfizer are companies to watch, with patents for their wonder drugs Viagra and Zoloft set to expire - forcing them to scour the world for a new product. Mr Evans likes Acrux, Nanosonics and ImpediMed as well, with ImpediMed a particular favourite among brokers. Nanosonics is currently waiting for approval from the US Food and Drug Administration for its Trophon EPA product. The firm has also secured a distribution agreement with General Electric?s health division and has a "buy" recommendation from the one broker covering the stock. Acrux is looking to move into AndroGel?s US market and has a implied 44 per cent return over the next year according to broker target price estimates.
 
watchlist Created with Sketch. Add ACR (ASX) to my watchlist
(20min delay)
Last
5.8¢
Change
0.003(5.45%)
Mkt cap ! $16.86M
Open High Low Value Volume
5.5¢ 5.8¢ 5.4¢ $73.70K 1.303M

Buyers (Bids)

No. Vol. Price($)
2 76865 5.6¢
 

Sellers (Offers)

Price($) Vol. No.
5.8¢ 101900 2
View Market Depth
Last trade - 16.10pm 12/09/2024 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.